← All trials
NCT05164081
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2022
- Primary completion
- Jan 31, 2026
- Completion date
- Jan 31, 2027
- First posted
- Dec 20, 2021
- Last posted
- Dec 20, 2021
- Enrollment
- 7000
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Umea UniversityLead sponsor
- Umea UniversityOverall official - principal investigator
- Västerbotten County CouncilCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.